Abstract
Meningioma (MEN) is a common central nervous system disease. Accumulating evidence indicated that long non-coding RNA maternally expressed gene 3 (MEG3) participated in the progression of MEN. However, the potential mechanisms of MEG3 in altering the aggressive phenotypes of MEN need further exploration. Levels of MEG3, microRNA (miR)-29c, and A-kinase anchor protein 12 (AKAP12) were determined using quantitative real-time Polymerase Chain Reaction (qRT-PCR) assay. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were performed to verify the relationship between miR-29c and MEG3 or AKAP12. The protein level of AKAP12 was detected by western blot. Moreover, cell-cycle arrest, migration, invasion, and proliferation were assessed by flow cytometry, wound healing, transwell assays, and CCK-8 assay, respectively. Levels of MEG3 and AKAP12 were downregulated, while miR-29c was effectively increased in MEN tissues and cell line. Mechanically, MEG3 was a sponge of miR-29c to regulate the expression of AKAP12. Functionally, increase of MEG3 diminished cell-cycle, migration, invasion, and proliferation in MEN cells, and reintroduction of miR-29c could eliminate these effects. In addition, AKAP12 depletion overturned the inhibitory effects of miR-29c absence on cell-cycle, migration, invasion, and proliferation in vitro. Also, AKAP12 was co-regulated by MEG3/miR-29c axis. MEG3 mediated the aggressive behaviors of MEN cells via miR-29c/AKAP12 axis, supporting that MEG3 served as a promising biomarker for the diagnosis and treatment of human MEN.
Highlights
Meningioma (MEN) belongs to the central nervous system disease with 30–40% morbidity [1]
maternally expressed gene 3 (MEG3) Was Low-Expressed, While Mir-29c Was Upregulated in MEN Tissues
Relative operating characteristic curves (ROC) analysis was carried out, and the area under the relative operating characteristic curves (ROC) curves (AUC; 0.85) showed that MEG3 might be a potential marker in MEN progression (Figure 1B)
Summary
Meningioma (MEN) belongs to the central nervous system disease with 30–40% morbidity [1]. MEN is classified according to the classification of the World Health Organization (WHO). MEN is regarded as a type of general neoplasm that derived from the meningeal coverings of the brain or spinal cord. Most of MEN is classified as benign tumors in qualitative classification [2, 3], the malignant MEN usually occurs with rapid growth and metastasis [4]. Continuous studies have achieved development on diagnosis and therapy for MEN, but the occurrence and recurrence of MEN is still pessimistic due to the ambiguous pathogenesis [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
